Oscar Millet (CEO)

Oscar is doctor in organic chemistry and chemical engineer. He currently is the Group Leader at the Precision Medicine and Metabolism Laboratory of the CIC bioGUNE, has in-depth expertise in the use of nuclear magnetic resonance (NMR) for the study of biologically relevant proteins and enzymes.

Joaquín Castilla (CSO)

Joaquín obtained a Degree in Pharmacy . In 2009, he was recipient of an IKERBasque Research Professor and currently he is a Group Leader at the Prion Lab at CIC bioGUNE. He has published more than 110 articles.

Ganeko Bernardo-Seisdedos (Project manager)

Ganeko obtained a PhD in Molecular Biology and Biomedicine. Since 2016 he is member of Atlas Molecular Pharma and has been involved in the design and development of Chassys™ platform.

Hasier Eraña (Project manager)

Hasier obtained a PhD in Molecular Biology and Biomedicine. He worked in the same institute as post-doctoral researcher until 2016, and in 2017, he joined Atlas to develop the Prion disease pipeline.

Jorge Moreno (Staff scientist)

Jorge performed his PhD at CIC bioGUNE in Neurosciences. In ATLAS, he has continued his work on the development of therapeutic strategies for prion diseases and as responsible of most of the studies in animal models.

María de los Reyes Luque
(Ph. D. student)

María de los Reyes obtained a Master’s degree in Medicines research, development, control and innovation. She is currently doing a PhD focused on the use of ciclopirox and other pharmacological chaperones in porphyria cutanea tarda.

Riccardo Scarin (Ph. D. student)

Riccardo obtained a Master Degree in Pharmaceutical Biotechnology at University of Padua. He is currently doing a PhD in Atlas Molecular Pharma, focusing on the characterization of ligand-protein interaction with the aim of developing a Pharmacological Chaperon for the treatment of Tyrosinemia type I.



Jorge Tejero (Delvy, CFO)
José M Aparicio (Accounting)
Mada Rodriguez (Personnel)